Abstract:Abstract In addition to the role of programmed cell death ligand 1 (PD-L1) in facilitating tumour cells escape from immune surveillance, it is considered as a crucial effector in transducing intrinsic signals to promote tumour development. Our previous study has pointed out that PD-L1 promotes non-small cell lung cancer (NSCLC) cell proliferation, but the mechanism remains elusive. Here we first demonstrated that PD-L1 expression levels were positively correlated with p-MerTK levels in patient samples and NSCLC cell lines. In addition, PD-L1 knockdown led to the reduced phosphorylation level of MerTK in vitro. We next showed that PD-L1 regulated NSCLC cell proliferation via Gas6/MerTK signaling pathway in vitro and in vivo. To investigate the underlying mechanism, we unexpectedly found that PD-L1 translocated into the nucleus of cancer cells which was facilitated through the binding of Karyopherin β1 (KPNB1). Nuclear PD-L1 (nPD-L1), coupled with transcription factor Sp1, regulated the synthesis of Gas6 mRNA and promoted Gas6 secretion to activate MerTK signaling pathway. Taken together, our results shed light on the novel role of nPD-L1 in NSCLC cell proliferation and reveal a new molecular mechanism underlying nPD-L1-mediated Gas6/MerTK signaling activation. All above findings provide the possible combinational implications for PD-L1 targeted immunotherapy in the clinic.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role and mechanism of PD - L1 (programmed death - ligand 1) in non - small - cell lung cancer (NSCLC) cell proliferation. Specifically, the researchers found that PD - L1 is not only expressed on the cell membrane, but also can enter the nucleus through KPNB1 - mediated nuclear transport, forming intranuclear PD - L1 (nPD - L1). nPD - L1 binds to the transcription factor Sp1, regulates the synthesis of Gas6 mRNA, promotes the secretion of Gas6, thereby activating the MerTK signaling pathway and promoting the proliferation of NSCLC cells. Therefore, this study aims to reveal the new molecular mechanism of nPD - L1 in NSCLC cell proliferation through the Gas6/MerTK signaling axis, and provide new potential strategies for PD - L1 - targeted immunotherapy. ### Main findings: 1. **Correlation between PD - L1 and p - MerTK**: The study found that the expression level of PD - L1 was positively correlated with the level of p - MerTK (the phosphorylated form of MerTK) in NSCLC tissue samples. 2. **PD - L1 regulates NSCLC cell proliferation**: By knocking down or overexpressing PD - L1, the researchers found that PD - L1 could significantly affect the proliferation of NSCLC cells. PD - L1 knockdown inhibited cell proliferation, while PD - L1 overexpression promoted cell proliferation. 3. **Gas6/MerTK signaling pathway**: Further research showed that PD - L1 regulates the proliferation of NSCLC cells through the Gas6/MerTK signaling pathway. PD - L1 overexpression up - regulated the transcription and secretion of Gas6, and then activated the MerTK signaling pathway. 4. **KPNB1 - mediated PD - L1 nuclear transport**: The study found that KPNB1 is a key protein in PD - L1 nuclear transport. PD - L1 enters the nucleus by binding to KPNB1, forms nPD - L1, and then regulates the transcription of Gas6. 5. **In vivo experimental verification**: In a mouse xenograft tumor model, PD - L1 overexpression promoted tumor growth, and the MerTK inhibitor UNC2025 could partially reverse this effect. ### Conclusion: This study for the first time demonstrated the important role of KPNB1 - mediated PD - L1 nuclear transport in NSCLC cell proliferation, and revealed a new mechanism by which nPD - L1 promotes NSCLC cell proliferation through the Gas6/MerTK signaling pathway. These findings provide a theoretical basis for the development of new immunotherapy methods targeting PD - L1.

KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway

6P Mechanisms of Regulating PD-L1 Expression in Non-Small Cell Lung Cancer During EMT Process

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

PD‐L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF ‐β1/ SMAD4 expression

Preliminary Mechanisms of Regulating PD‑L1 Expression in Non‑small Cell Lung Cancer During the EMT Process.

MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β

PTP1B Promotes Cell Proliferation and Metastasis Through Activating Src and ERK1/2 in Non-Small Cell Lung Cancer

ZNF148/PFKP/PD-L1 axis promotes non-small cell lung cancer proliferation, migration and glycolysis

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

PD-L2 mediates tobacco smoking-induced recruitment of regulatory T cells via the RGMB/NFκB/CCL20 cascade

USP51/PD‐L1/ITGB1‐deployed juxtacrine interaction plays a cell‐intrinsic role in promoting chemoresistant phenotypes in non‐small cell lung cancer

Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC

KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer

In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.

KRAS Mutants to Regulate PD-L1 Expression Through NF-ƘB and HIF-1α Pathways in Non-Small Cell Lung Cancer Cells.

Mechanism of the KIAA1429/KLF1/PD-L1 Axis in Regulating Immune Escape in Non-small Cell Lung Cancer

PD-L1 Interacts with Frizzled 6 to Activate Β-Catenin and Form a Positive Feedback Loop to Promote Cancer Stem Cell Expansion

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

Evaluation of the roles and regulatory mechanisms of PD-1 target molecules in NSCLC progression

NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis